Beneficial effects of melatonin in a rat model of sporadic Alzheimer’s disease
- 681 Downloads
Melatonin synthesis is disordered in patients with Alzheimer’s disease (AD). To determine the role of melatonin in the pathogenesis of AD, suitable animal models are needed. The OXYS rats are an experimental model of accelerated senescence that has also been proposed as a spontaneous rat model of AD-like pathology. In the present study, we demonstrate that disturbances in melatonin secretion occur in OXYS rats at 4 months of age. These disturbances occur simultaneously with manifestation of behavioral abnormalities against the background of neurodegeneration and alterations in hormonal status but before the signs of amyloid-β accumulation. We examined whether oral administration of melatonin could normalize the melatonin secretion and have beneficial effects on OXYS rats before progression to AD-like pathology. The results showed that melatonin treatment restored melatonin secretion in the pineal gland of OXYS rats as well as the serum levels of growth hormone and IGF-1, the level of BDNF in the hippocampus and the healthy state of hippocampal neurons. Additionally, melatonin treatment of OXYS rats prevented an increase in anxiety and the decline of locomotor activity, of exploratory activity, and of reference memory. Thus, melatonin may be involved in AD progression, whereas oral administration of melatonin could be a prophylactic strategy to prevent or slow down the progression of some features of AD pathology.
KeywordsAlzheimer’s disease Melatonin Neurodegeneration OXYS rats
We thank Dr. Vadim V. Yanshole of the International Tomography Center SB RAS, for assistance with the liquid chromatography with mass spectrometry experiments. This work was supported by a grant from the Russian Foundation for Basic Research (project # 12-04-00091) and partially by grants from the government of the Russian Federation # 2012-220-03-435 and # 14.B25.31.0033. The mass spectrometric analysis involved financial support by the Russian Scientific Foundation (project # 14-14-00056).
Conflict of interest
The authors declare that they have no competing financial interests.
- Andersen P, Morris R, Amaral D, Bliss T, O’Kneefe J (2007) The Hippocampus Book. Oxford University Press, Inc., New YorkGoogle Scholar
- Castellano JM, Deane R, Gottesdiener AJ, Verghese PhB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM (2012) Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci USA 109:15502–15507CrossRefPubMedCentralPubMedGoogle Scholar
- Kolosova NG, Stefanova NA, Muraleva NA, Skulachev VP (2012) The mitochondria-targeted antioxidant SkQ1 but not N-acetylcysteine reverses aging-related biomarkers in rats. Aging (Albany NY) 4:686–694Google Scholar
- Paxinos G, Watson CH (2007) The rat brain in stereotaxic coordinates, 6th edn. Elsevier, SydneyGoogle Scholar
- Shcheglova TV, Amstislavskaya TG, Kolosova NG (2002) Serotonin metabolism in the brain structures of prematurely ageing OXYS rats. Neurochemistry 19:269–273Google Scholar
- Snytnikova OA, Tsentalovich YP, Stefanova NA, Fursova AZh, Kaptein R, Sagdeev RZ, Kolosova NG (2012) The therapeutic effect of mitochondria-targeted antioxidant SkQ1 and Cistanche deserticola is associated with increased levels of tryptophan and kynurenine in the rat lenses. Dokl Biochem Biophys 447:300–303CrossRefPubMedGoogle Scholar
- Stefanova NA, Kozhevnikova OS, Vitovtov AO, Maksimova KYi, Logvinov SV, Rudnitskaya EA, Korbolina EE, Muraleva NA, Kolosova NG (2014a) Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease. Cell Cycle 13:1–12CrossRefGoogle Scholar